title: The use of high dosages of transdermal buprenorphine for pain management in palliative cancer patients: a case study.
abstract: Pain is a prevalent condition in patients with cancer, particularly in advanced stages of cancer. Although strong opioids are the mainstay of cancer pain management protocols, patients are often undertreated. Transdermal buprenorphine is currently available for the treatment of moderate to severe cancer pain and severe pain which does not respond to nonopioid analgesics; patch doses of 35, 52.5 and 70 µg/h are available (applied for up to 96 h), with no more than 2 transdermal patches at the same time, regardless of the strength. To date, there are no published reports in the literature of the use of high-dose transdermal buprenorphine (>140 µg/h). Herein, we present 2 cases of palliative cancer patients who received transdermal buprenorphine at doses titrated up to 210 and 175 µg/h, respectively, for the management of pain. Transdermal buprenorphine titrated to doses >140 µg/h provided adequate pain control and was well tolerated. Future studies to confirm these initial observations are warranted.
authors.affiliation: Department of Oncology, KU Leuven, Leuven, Belgium ; Leuven Cancer Institute, Leuven, Belgium.
authors.forename: Paul
authors.initials: P
authors.lastname: M J Clement
authors.forename: Benoit
authors.initials: B
authors.lastname: Beuselinck
authors.forename: Karen
authors.initials: K
authors.lastname: Van Beek
authors.forename: P
authors.initials: P
authors.lastname: Georgette Mertens
authors.forename: Paul
authors.initials: P
authors.lastname: Cornelissen
authors.forename: Johan
authors.initials: J
authors.lastname: Menten
keywords: Cancer pain; Palliative cancer; Transdermal buprenorphine